|
May 15
|
Eisai sets new revenue target for Alzheimer’s drug Leqembi
|
|
May 15
|
UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
|
|
May 14
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
|
|
May 14
|
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
|
|
May 13
|
15 Most Depressed States in the US
|
|
May 9
|
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
|
|
May 8
|
Jeff Auxier's Firm Dissolves Textainer Group Position, Trims Biogen
|
|
May 8
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
May 8
|
Q1 2024 Abcellera Biologics Inc Earnings Call
|
|
May 4
|
Morgan Stanley’s Top 15 Stock Picks for 2024
|
|
May 2
|
Biogen Reports Progress on Corporate Responsibility Priorities
|
|
May 1
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Apr 29
|
7 Retirement Stocks to Buy at a 52-Week Low in April
|
|
Apr 29
|
10 Most Promising Stocks to Buy Before They Take Off
|
|
Apr 28
|
Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Apr 27
|
Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
|
|
Apr 26
|
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
|
|
Apr 26
|
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
|
|
Apr 26
|
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
|
|
Apr 25
|
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
|